Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 2/20 | 0.54 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18095028 | 0.84 | PDE4D (0.51) | NR1H3NR1H2CNR1TSHRPOLB | |
| SCHEMBL7890537 | 0.75 | RXFP1 (0.70) | TSHRRAB9AMAPTLMNAMEN1 | |
| SCHEMBL8233185 | 0.73 | CNR1 (0.48) | CNR1TSHRPOLBMAPTHPGD | |
| SCHEMBL21632739 | 0.73 | CNR1 (0.55) | CNR1TSHRMAPTHPGDSMN1; SMN2 | |
| SCHEMBL23777943 | 0.72 | PDE4D (0.62) | CNR1TSHRPOLBRAB9AMAPT | |
| SCHEMBL21632706 | 0.72 | PDE4D (0.60) | CNR1TSHRPOLBMAPTSMN1; SMN2 | |
| SCHEMBL21632726 | 0.72 | PDE4D (0.61) | CNR1TSHRPOLBMAPTSMN1; SMN2 | |
| SCHEMBL21659870 | 0.72 | TSHR (0.48) | TSHRPOLBF2RAB9AMAPT | |
| SCHEMBL15631910 | 0.71 | LMNA (0.68) | CNR1TSHRMAPTHPGDSMN1; SMN2 | |
| SCHEMBL21632725 | 0.71 | MAPT (0.49) | CNR1TSHRF2MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10793531-B2 | Triazole derivatives and their use as PDE4 activators | MIRONID LIMITED (GB) | 2020-10-06 | — | — | US | claimed |
| EP-3271338-B1 | TRIAZOLE DERIVATIVES AND THEIR USE AS PDE4 ACTIVATORS | MIRONID LTD (GB) | 2019-09-04 | — | — | EP | claimed |
| US-10385027-B2 | Triazole derivatives and their use as PDE4 activators | MIRONID LIMITED (GB) | 2019-08-20 | — | — | US | claimed |
| US-20180057466-A1 | TRIAZOLE DERIVATIVES AND THEIR USE AS PDE4 ACTIVATORS | MIRONID LIMITED (GB) | 2018-03-01 | — | — | US | claimed |
| US-10793531-B2 | Triazole derivatives and their use as PDE4 activators | MIRONID LIMITED (GB) | 2020-10-06 | — | — | US | disclosed |
| US-10793531-B2 | Triazole derivatives and their use as PDE4 activators | MIRONID LIMITED (GB) | 2020-10-06 | — | — | US | disclosed |
| EP-3271338-B1 | TRIAZOLE DERIVATIVES AND THEIR USE AS PDE4 ACTIVATORS | MIRONID LTD (GB) | 2019-09-04 | — | — | EP | disclosed |
| EP-3271338-B1 | TRIAZOLE DERIVATIVES AND THEIR USE AS PDE4 ACTIVATORS | MIRONID LTD (GB) | 2019-09-04 | — | — | EP | disclosed |
| US-10385027-B2 | Triazole derivatives and their use as PDE4 activators | MIRONID LIMITED (GB) | 2019-08-20 | — | — | US | disclosed |
| US-10385027-B2 | Triazole derivatives and their use as PDE4 activators | MIRONID LIMITED (GB) | 2019-08-20 | — | — | US | disclosed |
| US-20180057466-A1 | TRIAZOLE DERIVATIVES AND THEIR USE AS PDE4 ACTIVATORS | MIRONID LIMITED (GB) | 2018-03-01 | — | — | US | disclosed |
| US-20180057466-A1 | TRIAZOLE DERIVATIVES AND THEIR USE AS PDE4 ACTIVATORS | MIRONID LIMITED (GB) | 2018-03-01 | — | — | US | disclosed |
| EP-3271338-A1 | TRIAZOLE DERIVATIVES AND THEIR USE AS PDE4 ACTIVATORS | Mironid Limited (GB) | 2018-01-24 | — | — | EP | disclosed |
| WO-2016151300-A1 | TRIAZOLE DERIVATIVES AND THEIR USE AS PDE4 ACTIVATORS | MIRONID LIMITED (GB) | 2016-09-29 | — | — | WO | disclosed |
| WO-2016151300-A1 | TRIAZOLE DERIVATIVES AND THEIR USE AS PDE4 ACTIVATORS | MIRONID LIMITED (GB) | 2016-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385027-B2 | Triazole derivatives and their use as PDE4 activators | PDE4A, PDE4B, PDE3A | NR1H3 2306/4885NR1H2 2209/4885CNR1 2309/4885 |
| US-10793531-B2 | Triazole derivatives and their use as PDE4 activators | PDE4A, PDE4B, PDE3A | NR1H3 2306/4885NR1H2 2209/4885CNR1 2309/4885 |
| US-20180057466-A1 | TRIAZOLE DERIVATIVES AND THEIR USE AS PDE4 ACTIVATORS | PDE4A, PDE4B, PDE3A | NR1H3 2306/4885NR1H2 2209/4885CNR1 2309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.